Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine (EyeCRO)
- Development stage
- Preclinical
- Lead developer
- EyeCRO
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Cyclosporine A is a small molecule calcineurin inhibitor formulated in the proprietary MiDROPS (Microemulsion Drug Delivery System) platform for topical ophthalmic delivery. Developed by MiDROPS, this candidate is currently in preclinical development for the treatment of autoimmune uveitis. The mechanism of action involves the inhibition of calcineurin, a calcium-dependent phosphatase, which prevents the dephosphorylation and nuclear translocation of the Nuclear Factor of Activated T-cells (NFAT). This blockade suppresses the transcription of interleukin-2 (IL-2) and other pro-inflammatory cytokines, effectively inhibiting T-cell activation and the subsequent inflammatory cascade associated with uveitis. The MiDROPS platform is designed to enhance the solubility and ocular penetration of hydrophobic drugs like cyclosporine, potentially allowing for more effective delivery to the posterior segments of the eye compared to standard topical formulations.
- Other names
- Cyclosporine ACsAMiDROPS Cyclosporine
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)PPIF (Cyclophilin D)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on cyclosporine (EyeCRO).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine (EyeCRO).